Arrowstreet Capital
NAGE

Arrowstreet Capital’s Niagen Bioscience NAGE Stock Holding History

Arrowstreet Capital’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.74M Sell
1,171,215
-1,207,222
-51% -$4.9M ﹤0.01% 1377
2026
Q1 		$10.5M Buy
2,378,437
+761,685
+47% +$4.11M 0.01% 931
2025
Q4 		$10.3M Buy
1,616,752
+179,954
+13% +$1.25M 0.01% 919
2025
Q3 		$13.4M Buy
1,436,798
+317,418
+28% +$3.2M 0.01% 864
2025
Q2 		$16.1M Buy
1,119,380
+129,507
+13% +$1.28M 0.01% 756
2025
Q1 		$6.83M Buy
989,873
+326,917
+49% +$2.05M 0.01% 917
2024
Q4 		$3.52M Buy
662,956
+492,148
+288% +$2.69M ﹤0.01% 1113
2024
Q3 		$623K Buy
+170,808
New +$538K ﹤0.01% 1484

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowstreet Capital's NAGE Position: Q2 2026 in Review

Arrowstreet Capital reduced its Niagen Bioscience (NAGE) stake by 51% in Q2 2026, selling an estimated $4.9M and leaving 1,171,215 shares worth $3.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1377.

Arrowstreet Capital first reported a position in NAGE in Q3 2024 and has held it in 8 quarters since. The position peaked at $16.1M in Q2 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Arrowstreet Capital held 1,171,215 shares of Niagen Bioscience worth $3.74M as of Q2 2026.
  • Arrowstreet Capital sold 1,207,222 Niagen Bioscience shares in Q2 2026, an estimated $4.9M.
  • Niagen Bioscience made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1377 holding.
  • Arrowstreet Capital first reported a position in Niagen Bioscience in Q3 2024 and has held it in 8 quarters since.
  • Arrowstreet Capital's Niagen Bioscience position peaked at $16.1M in Q2 2025.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.